智通财经APP讯，安必平(688393.SH)披露2025年度业绩快报，2025年度实现营业总收入3.47亿元，同比 下降26.24%;归属于母公司所有者的净利润亏损4497.17万元，同比由盈转亏。 报告期内，国家集采政策全面落地实施，公司HPV产品线售价同比大幅下降，导致该业务收入减少约 4,650万元。报告期内，公司主动优化业务结构，聚焦主营业务收入拓展，相应减少代理产品业务规 模。此外，为加速市场渗透，公司积极推进渠道策略调整，扩大经销渠道比重，产品销售单价同比下 降，短期内对整体毛利产生一定影响。 ...

报告期内，国家集采政策全面落地实施，公司HPV产品线售价同比大幅下降，导致该业务收入减少约 4,650万元。报告期内，公司主动优化业务结构，聚焦主营业务收入拓展，相应减少代理产品业务规 模。此外，为加速市场渗透，公司积极推进渠道策略调整，扩大经销渠道比重，产品销售单价同比下 降，短期内对整体毛利产生一定影响。 安必平(688393.SH)披露2025年度业绩快报，2025年度实现营业总收入3.47亿元，同比下降26.24%;归属 于母公司所有者的净利润亏损4497.17万元，同比由盈转亏。 ...

（文章来源：证券日报） 证券日报网讯 2月27日，安必平发布2025年度业绩快报公告称，公司2025年实现营业总收入34726.91万 元，同比下降26.24%。 ...

报告期内，公司主动优化业务结构，聚焦主营业务收入拓展，相应减少代理产品业务规模。此外，为加 速市场渗透，公司积极推进渠道策略调整，扩大经销渠道比重，产品销售单价同比下降，短期内对整体 毛利产生一定影响。 格隆汇2月27日丨安必平(688393.SH)公布2025年年度业绩快报，报告期内，公司实现营业收入34,726.91 万元，同比下降26.24%；实现归属于母公司所有者的净利润-4,497.17万元，同比下降311.22%；实现归 属于母公司所有者的扣除非经常性损益的净利润-6,589.54万元，同比下降562.30%。 ...

证券代码：688393 证券简称：安必平 公告编号：2026-006 广州安必平医药科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司 2025 年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 34,726.91 | 47,079.01 | -26.24 | | 营业利润 | -5,191.28 | 1,100.18 | -571.86 | | 利润总额 | -5,603.14 | 943.44 | -693.91 | | 归属于母公司所有 者的净利润 | -4,497.17 | 2,129.13 | -311.22 | | 归属于母公司所有 | | | | | 者的扣除非经常性 | ...

安必平发布业绩快报，2025年度实现营业总收入3.47亿元，同比下降26.24%；净利润亏损4497.17万 元，上年同期净利润为2129.13万元。报告期内，国家集采政策全面落地实施，公司HPV产品线售价同 比大幅下降，导致该业务收入减少约4650万元。 ...

Core Insights - The company has several noteworthy events to watch in the coming months regarding its stock performance [1] Recent Events - The company's cervical cytology AI class III certification is expected to be approved between late March and early April 2026, which may provide a monetization opportunity for its AI-assisted diagnostic business [2] - Nanjing Qianjing Venture Capital Partnership announced on January 18, 2026, its plan to reduce its holdings by up to 1.61% of the company's total share capital, necessitating attention to the implementation progress [2] Company Status - The management expressed confidence in returning to positive growth and achieving net profit recovery in 2026, primarily based on business adjustments and AI initiatives [3] Policy Environment - The National Healthcare Security Administration's guideline released in December 2025 regarding the pricing of pathological medical services may stimulate demand for digital pathology tools, although specific pricing will require negotiations with local authorities [4] Stock Price Situation - Technical analysis indicates that the stock price has recently tested Fibonacci resistance levels, with overbought stochastic indicators suggesting a potential short-term bearish correction risk [5] Future Development - The company plans to launch new pathology AI products annually starting in 2028 to enhance its product line [6]

Core Viewpoint - Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. is expected to report a significant net loss for the fiscal year 2025, with projections indicating a loss between 52 million to 42 million yuan, representing a year-on-year decrease of 344.23% to 297.26% compared to the previous year [3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [2]. - The expected net profit attributable to the parent company is projected to be between -52 million to -42 million yuan, a decrease of 73.29 million to 63.29 million yuan compared to the previous year [3]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -72 million to -62 million yuan, a decrease of 86.25 million to 76.25 million yuan compared to the previous year [3]. Group 2: Previous Year Performance - In the previous year, the total profit was 9.43 million yuan, with a net profit attributable to the parent company of 21.29 million yuan [5]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 14.25 million yuan [5]. - The earnings per share for the previous year was 0.23 yuan [6]. Group 3: Reasons for Performance Change - The company's operating income has declined, primarily due to the implementation of national centralized procurement policies, which significantly reduced the selling price of HPV product lines, leading to a revenue decrease of approximately 46.5 million yuan [7]. - The gross profit margin for the HPV product line has also been under pressure, resulting in a gross profit decrease of about 46 million yuan [7]. - The company is actively optimizing its business structure and focusing on expanding its main business revenue while reducing the scale of agency product business [7]. - To build long-term competitive advantages, the company is increasing its investment in product research and innovation, particularly in the fields of pathological intelligence and tumor companion diagnostics, which has led to an increase in operating costs [7]. - The company has made provisions for asset impairment in accordance with accounting standards and policies [7]. Group 4: Non-Operating Gains and Losses - The increase in non-recurring gains and losses is mainly due to increased investment income from associated companies [9].

Core Viewpoint - Anbipin (688393.SH) expects to report a net profit attributable to shareholders of the parent company for the year 2025 in the range of -52 million to -42 million yuan, indicating a significant loss compared to the previous year [1] Financial Performance - The anticipated loss represents a decrease of 73.29 million to 63.29 million yuan compared to the same period last year [1] - This reflects a year-on-year decline of 344.23% to 297.26% [1]

Group 1 - The company, Anbiping (688393.SH), expects to report a net loss attributable to shareholders of the parent company ranging from -52 million to -42 million yuan for the year 2025 [1] - This projected loss represents a significant decline compared to the previous year's statutory disclosure data, with a decrease of 73.29 million to 63.29 million yuan [1] - The year-on-year decrease in net profit is estimated to be between 344.23% and 297.26% [1]